ESTRO 2024 - Abstract Book

S721

Clinical - Breast

ESTRO 2024

axillary relapse. Time to RT < 4 months resulted in better OS (p= 0.002); LRR resulted 6%. pCR was not associated to better OS (p=0.5) and DFS (p=0.3). The benefit of a time to RT ≤ 4 months was statistically significant both interms of DFS (HR: 3.77, 95% CI: 1.58-9.55) and OS (HR:3.22, 95% CI: 0.19-9.51). RT was well tolerated: 12% of patients reported an acute toxicity > 2.

Conclusion:

NAC resulted a good treatment in order to downstage disease before performing local treatment: about one third of our patients achieved a pCR. In this setting of patients, performing RT until 4 months could ensure a benefit from treatment in terms of OS. Prospective studies and clinical trial are needed in order to strengthen clinical guidelines.